Every 10-Q that Adaptive Biotechnologies Corporation (ADPT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ADPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADPT filings page.
Adaptive Biotechnologies Corporation reported Q2 2026 revenue of $71.6 million, up from $58.9 million a year earlier, driven mainly by MRD service revenue. Immune Medicine revenue was smaller, and net loss attributable to the company widened to $39.8 million, or $0.25 per share, including a $23.7 million loss on extinguishing a revenue interest liability.
Cash, cash equivalents and marketable securities increased to $371.7 million at June 30, 2026. The company issued $345.0 million of 0% convertible senior notes due 2031, used $156.9 million of the proceeds to repurchase all Revenue Interests, spent $25.0 million to repurchase 1,451,800 shares, and entered capped call transactions intended to limit dilution from the notes.
MRD generated positive Adjusted EBITDA, while Immune Medicine remained loss-making. Management plans to separate the MRD and Immune Medicine businesses by identifying a preferred separation path by year-end 2026 and will wind down the Adaptive Immunosequencing research-use-only service to focus Immune Medicine on its TCR-antigen dataset and target discovery platform.
Adaptive Biotechnologies reported higher revenue and a smaller loss for the quarter ended March 31, 2026. Total revenue rose to $70.9 million from $52.4 million, driven by Minimal Residual Disease (MRD) revenue of $67.1 million, including $9.0 million of regulatory milestone revenue.
Immune Medicine revenue declined to $3.8 million following termination of the Genentech collaboration. Net loss attributable to the company narrowed to $20.0 million, or $0.13 per share, from $29.9 million. Adjusted EBITDA improved to a loss of $2.5 million from $12.7 million. Cash, cash equivalents and marketable securities totaled $237.2 million.
Adaptive Biotechnologies (ADPT) reported stronger Q3 2025 results. Revenue rose to $93.973 million from $46.435 million a year ago, and the company posted net income of $9.545 million (basic and diluted EPS $0.06) versus a prior-year loss. Year-to-date revenue reached $205.295 million with a net loss of $45.878 million.
Growth reflected higher MRD service revenue and a spike in Immune Medicine collaboration revenue, including $33.742 million recognized from the Genentech collaboration. On August 13, 2025, the Genentech Agreement was terminated (effective February 9, 2026); remaining deferred revenue was recognized and the company is no longer eligible for future milestones or royalties.
Cash and cash equivalents were $55.034 million, with $157.735 million in short‑term marketable securities. Deferred revenue decreased to $42.543 million from $82.945 million at year‑end, reflecting revenue recognition. The revenue interest liability, net, was $131.838 million with an effective interest rate of 8.8%. Shares outstanding were 152,665,188 as of October 31, 2025.